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Nitric oxide (NO), a mediator of biological functions, has an antimicrobial activity against a variety of pathogens including
viruses. In this study, we found that a constitutive, low level of inducible NO synthase (iNOS) mRNA was expressed in the
EBV-infected gastric tissue-derived GT38 and GT39 cell lines, by analysis with the reverse transcription–polymerase chain
reaction (RT–PCR) and Southern blotting. Treatment of these cells with a specific NOS inhibitor, NG-monomethyl-L-arginine
(L-NMMA), induced the immediate-early, EBV transactivator gene BZLF1 protein ZEBRA, suggesting a significant increase in
EBV reactivation by L-NMMA. Northern blotting demonstrated that BZLF1 and BRLF1 transcripts were also induced by
12-O-tetradecanoylphorbol-13 acetate (TPA). Meanwhile, constitutive expression of iNOS mRNA was inhibited by TPA.
L-NMMA also enhanced TPA-induced expression of the BZLF1 gene. On the other hand, a NO donor, S-nitroso-N-
acetylpenicillamine (SNAP), which releases NO in an aqueous solution, inhibited the TPA-induced BZLF1 gene expression in
a dose-dependent manner at both mRNA and protein levels. These results demonstrated that NO is a regulatory factor in
maintaining virus latency via inhibiting EBV reactivation in the infected epithelial cells. © 1999 Academic Press
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Nitric oxide (NO) is an important signaling molecule
egulating a wide array of biological activities in neural,
ascular, and immune cells (Nathan, 1992). NO is gen-
rated from L-arginine and molecular oxygen in the pres-
nce of the enzyme NO synthase (NOS) (Moncada et al.,
991), which includes three different isoforms: neuronal
nNOS, NOS1), inducible (iNOS, NOS2), and endothelial
eNOS, NOS3), originally purified from neurons, cytokine-
ctivated macrophages, and endothelium, respectively
Nathan and Xie, 1994; Wang et al., 1997). The three NOS
soforms are expressed in wide range of cell types and
issues. Both eNOS and nNOS, calcium calmodulin-de-
endent enzymes, are constitutively expressed in endo-
helium and neurons (Bredt and Snyder, 1994; Yun et al.,
996). iNOS is a Ca21-independent high-output enzyme
hat was first described in macrophages stimulated with
nterferon-gamma (IFN-g) or bacterial lipopolysaccharide
LPS) (Stuehr and Marletta, 1985). But later it was found
hat iNOS can also be expressed in many other cell types
ncluding hepatocytes, endothelial cells, and smooth
uscle cells (Palmer et al., 1988; Nathan and Xie, 1994;
ang et al., 1998). Cells in which NO synthase is induced
aintain a sustained flux of NO which can be cytotoxic
or tumor cells or pathogens (Nathan and Hibbs, 1991).
lthough for reasons yet unclear human cells express
ess iNOS mRNA in response to cytokines than rodent
1 To whom the correspondence should be addressed. Fax: 181-859-
E4-8042. E-mail: sairen@grape.med.tottori-u.ac.jp.
375ells (Granger 1991). In particular, INF-g-induced NO
roduction by macrophages has been implicated in re-
istance to intracellular pathogens, such as parasites
Stenger et al., 1994), fungi (Nakamura et al., 1994), my-
obacteria (Flesh et al., 1994), and viruses, such as
ctromelia virus (Karupiah et al., 1993), vaccinia virus
Harris et al., 1995), Friend leukemia murine retrovirus
Akarid et al., 1995), herpes simplex virus type 1 (Croen,
993), and murine hepatitis virus type 3 (Pope et al.,
998). In the case of Epstein–Barr virus (EBV), NO has
een shown to inhibit viral reactivation in EBV-infected B
ells (Mannick et al., 1994) and DNA replication in EBV
uperinfected Raji cells (Kawanishi, 1995). Although the
echanisms for the antiviral action of NO have not been
larified, the multiplicity of host enzymes it targets makes
t possible that multiple alterations in host cell proteins
re involved. These observations also lead us to postu-
ate that NO might also be an important factor in the
ost-EBV relationship.
EBV is a human herpesvirus that causes infectious
ononucleosis and is associated with various lymphoid
nd some epithelial malignancies (Rickinson et al., 1996),
or example, Burkitt’s lymphoma, nasopharyngeal carci-
oma (Pathmanathan et al., 1995), and gastric carcinoma
Iwasaki et al., 1998). There is increasing evidence that
inks EBV infection to epithelial cell diseases. The very
lose relationship between EBV and nasopharyngeal
arcinoma is already well known. However, little is
nown about the interaction between EBV and gastric
arcinoma. In latently infected cells, the lytic phase of
BV life cycle can be induced by compounds such as
0042-6822/99 $30.00
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376 GAO, TAJIMA, AND SAIRENJI2-O-tetradecanoylphorbol-13-acetate (TPA) (zur Hausen
978) or cross-linking of surface immunoglobulin
Takada 1984). These agents activate expression of the
iral immediate-early protein BZLF1, which is also termed
EBRA, EB1, Zta, or Z (Countryman and Miller, 1985;
hevallier-Greco et al., 1986; Takada et al., 1986). Con-
ersely, BZLF1 is repressed in EBV latent phase to pre-
ent the onset of the lytic phase and the eventual death
f the host cell. Previous report has shown that TPA
timulation in EBV-infected epithelial cell lines GT38 and
T39 can induce EBV reactivation from a latent phase to
lytic one (Takasaka et al., 1998). This findings is con-
istent with the possibility that EBV reactivation is NO
esponsive, which is supported by the evidence that Zta,
EBV transactivation factor which can initiate lytic EBV
nfection, is redox regulated, and in turn the redox gene
s involved in NO regulation (Sandau and Brune, 1996).
O is involved in EBV reactivation in lymphoma-derived
ell lines (Mannick et al., 1994).
We undertook the present study to investigate (1)
hether human gastric tissue-derived EBV-infected epi-
helial cell lines express iNOS mRNA, (2) the basis for a
orrelation between iNOS mRNA expression and EBV
eactivation, and (3) interactions of exogenous NO, TPA
timulation, and EBV reactivation. We found that the two
uman gastric tissue-derived cell lines GT38 and GT39
onstitutively express a low level of iNOS mRNA and that
O might play an important role in maintaining virus
atency through inhibiting EBV reactivation.
RESULTS
nducible NOS gene expression in GT38 and GT39
ell lines
iNOS gene expression is reported to varied among cell
ines and/or cell types (Mannick et al., 1994). To test
hether the EBV-positive gastric tissue-derived epithelial
ell lines GT38 and GT39 can express iNOS mRNA, we
erformed RT–PCR and Southern blotting analyses. At
he size (;729 bp) of the amplified product, we detected
NOS mRNA in both of them and in the control B95-8 cell
ine (Fig. 1), whereas we found that the iNOS mRNA
xpression level was much higher in B95-8 cells than
hat in GT38 and GT39 cells, and it was much higher in
T38 cells than that in GT39 cells. The iNOS mRNA was
ot detected by us in either normal gastric tissue or
BV-positive Akata cells, which have been reported to
xpress iNOS mRNA (Mannick et al., 1994). To further
haracterize iNOS mRNA expression level in the GT38
nd GT39 cell lines, Northern blotting and Griess reac-
ion (Green et al., 1982) were performed. We failed to
etect iNOS mRNA and NO, respectively (data not
hown), suggesting that the expression level was veryow. Gnduction of EBV reactivation by a specific
ompetitive inhibitor of NOS, L-NMMA
Toward understanding functions of constitutive iNOS
RNA expression, we analyzed the effects of NO on EBV
eactivation in GT38 and GT39 cells. NG-monomethyl-L-
rginine (L-NMMA), a specific competitive inhibitor of
OS, was used to examine the reactivation of EBV in
T38 cells. Western blot analysis showed that the gene
xpression of immediate-early EBV transactivator ZEBRA
rotein, a marker of EBV reactivation, was induced in a
ime-dependent manner after exposure to L-NMMA (Fig.
). ZEBRA expression began to appear at Day 1, became
igher at Day 3, reached a peak at Day 6, and then
ecreased at Day 8. A similar result was obtained in
T39 cells (data not shown). On the other hand, no
EBRA was detected in untreated cells. These results
how that latent EBV can be reactivated in GT38 and
FIG. 1. EBV-positive epithelial cell lines GT38 and GT39 constitutively
xpress iNOS mRNA. (A) cDNA was made from total RNAs from GT38,
T39, B95-8, Akata cell lines, and noncancerous gastric tissue (NCGT).
amples to which reverse transcriptase was (1RT) or was not (2RT)
dded are indicated. Equal amounts of each sample were PCR ampli-
ied using primers specific for either human iNOS or tubulin, and the
CR products were analyzed by Southern blotting. (B) Autoradiographic
RNA signals were quantitated by phosphor imager system and rela-
ive to tubulin mRNA.T39 cells by L-NMMA, which blocks NO synthesis, and
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377NITRIC OXIDE INHIBITS EBV REACTIVATIONupport the notion that endogenous NO can have an
nhibiting effect on EBV reactivation in these cells.
ffect of TPA on EBV immediate-early gene
xpression and iNOS mRNA expression
TPA can induce EBV reactivation in EBV-infected B cell
ines (zur Hausen et al., 1978). The EBV BZLF1 immedi-
te-early transactivator initiates the switch between la-
ent and productive infection in B cells (Countryman and
iller, 1985; Chevallier-Creco et al., 1986; Takata et al.,
986). We examined the induction of EBV BZLF1 imme-
iate-early transactivator by TPA treatment in the GT38
nd GT39 cell lines with Northern blot analysis. The
ZLF1 and BRLF1 genes were expressed in a time-
ependent manner as 1.0- and 3.0-kb-long mRNA, re-
pectively (Fig. 3A). Expression with time patterns dif-
ered. BRLF1 expression began to increase at 4 h,
eached a plateau at 8–12 h, and then decreased to a
ower level at 24 h after exposure to TPA. On the other
and, BZLF1 gene expression appear to be increased
ore rapidly, reached a plateau at 8–12 h and main-
ained that high level at least until 72 h after exposure to
PA. To investigate whether iNOS mRNA expression
ould be affected by TPA treatment, we further examined
he levels of iNOS mRNA in GT38 cells treated with TPA.
s shown in Fig. 3B, TPA treatment led to a marked
eduction in iNOS mRNA expression at 4, 8, and 12 h,
ollowed by reappearance of iNOS mRNA at 24 h after
reatment. The reduction of iNOS mRNA expression at
h after TPA treatment coincided with the appearance of
ZLF1 and BRLF1 transcripts. A similar result was ob-
erved in GT39 cells (data not shown); however, BZLF1
ene expression level was higher in GT39 cells than that
n GT38 cells (Fig. 3C). Taken together, these results
uggested that TPA induced EBV reactivation from latent
tate to lytic phase through inhibiting iNOS activation.
-NMMA enhances TPA-induced BZLF1 and BRLF1
ene expression
To further verify a role for NO in inhibiting EBV reacti-
ation, we analyzed whether L-NMMA could increase
FIG. 2. The NOS inhibitor L-NMMA reactivates latent EBV. GT38 cells
ere cultured with or without L-NMMA (5 mM). Fifty micrograms protein
rom the cells at Days 0, 1, 3, 6, and 8 after the addition of L-NMMA was
eparated electrophoretically, blotted onto membranes, and then im-
uno-reacted with anti-ZEBRA monoclonal antibodies.PA-induced BZLF1 and BRLF1 gene expressions. To sxamine this, GT38 cells were pretreated with L-NMMA
1, 2, or 5 mM) for 1 h and then treated with TPA for 8 h.
he TPA-induced expression levels of BZLF1 and BRLF1
ere increased by pretreatment with L-NMMA (Fig. 4A).
urthermore, to confirm whether L-NMMA increases
PA-induced BZLF1 translation, GT38 cells were pre-
reated with 5 mM L-NMMA prior to treatment with TPA
Fig. 4B). L-NMMA clearly increased subsequent TPA-
nduced ZEBRA expression, indicating that the interac-
ion between L-NMMA and TPA in EBV reactivation is
robably through a common pathway.
FIG. 3. TPA induces EBV immediate-early genes BZLF1 and BRLF1
xpression, but inhibits iNOS mRNA expression. GT38 and GT39 cells
ere cultured with or without TPA (20 ng/ml). (A) Total RNA from GT38
ells was extracted at 0, 4, 8, 12, 24, 48, and 72 h after exposure to TPA.
orthern hybridization was performed using BZLF1 probe. The same
lot was stripped with strip buffer and rehybridized for GAPDH. (B) The
ame samples were analyzed for iNOS mRNA expression at indicated
imes by RT–PCR Southern blotting. (C) Total RNA from GT38 and GT39
ells was extracted at 8 h after treatment with TPA. Northern hybrid-
zation was performed using a BZLF1 probe. The same blot was
tripped with strip buffer and rehybridized for GAPDH.
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378 GAO, TAJIMA, AND SAIRENJIffect of SNAP, a NO donor, on the TPA-induced
ZLF1 gene expression
To characterize in more detail the effects of endoge-
ous NO on EBV reactivation, we examined whether
xogenous NO also has a similar effect in inhibiting EBV
eactivation. The effect of NO donor S-nitroso-N-
cetylpenicillamine (SNAP) on EBV reactivation was
valuated. It is known that SNAP generates NO when
issolved in an aqueous solution, resulting in the forma-
ion of peroxynitrit (Gilad et al., 1997). GT38 cells were
retreated with SNAP for 1 h, then treated with TPA for
h more, and total RNA was then analyzed by Northern
lotting (Fig. 5A). SNAP was found to greatly inhibit the
PA-induced BZLF1 and BRLF1 gene expression in a
ose-dependent manner. BZLF1 gene expression was
ompletely inhibited at SNAP pretreatment concentration
f 1 mM. In addition, when the cells were cultured for 3
ays, Western blotting results showed that SNAP (1 mM)
ompletely inhibited the TPA-induced EBV reactivation in
he cells (Fig. 5B). Clearly, these results showed that
eactivation of latent EBV infection in GT38 and GT39
ells could be inhibited by exogenous NO.
DISCUSSION
This study demonstrates that a low level of iNOS
RNA is constitutively expressed in newly established
BV-positive epithelial cell lines GT38 and GT39 (Tajima
FIG. 4. L-NMMA enhances TPA-induced BZLF1 and ZEBRA expres-
ion. GT38 cells were pretreated with 1, 2, and 5 mM of L-NMMA for 1 h
nd treated thereafter with TPA (20 ng/ml) for 8 h. Northern (A) and
estern (B) blots were carried out as described in Figs. 2 and 3,
espectively.t al., 1998) and characterizes an apparent role of NO in wnhibiting EBV reactivation from latency. The iNOS mRNA
evels in GT38 and GT39 cells were so low that they were
etected by only RT–PCR but not by Northern blotting.
onstitutive iNOS mRNA expression was observed in
ach cell lines, but the level of iNOS mRNA in GT38 cells
as higher than that in GT39 cells. It was unknown why
e failed to detect iNOS mRNA in Akata cells, although
e have also used the other primer sets as described
reviously (Mannick et al., 1994). This is the first report
howing the constitutive iNOS mRNA expression in EBV-
nfected epithelial cell lines.
It has been shown that NO plays a physiological role
n human B cell biology by inhibiting apoptosis and EBV
eactivation (Mannick et al., 1994). Our results demon-
trate that reactivation of EBV in GT38 and GT39 cells is
lso inhibited by endogenously synthesized NO. For ex-
mple, the specific NOS inhibitor L-NMMA induced EBV
eactivation. This finding led us to propose that EBV
atency can be directly and/or indirectly associated with
NOS gene expression. TPA stimulated EBV replication in
hese cell lines and reduced constitutive iNOS mRNA
xpression. Extending our work on these results, we
urther found that L-NMMA not only has a similar effect
ut also synergistically promotes EBV reactivation. In
articular, NO (released by a NO donor, SNAP) itself
eutralized the effect of TPA on EBV reactivation. Clearly
here is close interaction between NO and TPA.
EBV reactivation can be induced by TPA (zur Hausen
t al., 1978). EBV reactivation from latency is initiated by
ZLF1 gene expression (Countryman and Miller, 1985;
FIG. 5. SNAP inhibits TPA-induced EBV reactivation. GT38 cells were
retreated with various concentrations of SNAP for 1 h prior to TPA (20
g/ml) treatment. (A) Total RNA was extracted at 8 h. (B) Protein was
xtract at 72 h after TPA treatment. Northern and Western blottings
ere carried out as described in Figs. 2 and 3, respectively.
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379NITRIC OXIDE INHIBITS EBV REACTIVATIONhevallier-Greco et al., 1986; Takada et al., 1986). It is
nown that BZLF1 promoter contains a TPA-responsive
lement regulating BZLF1 gene expression and conse-
uently EBV lytic cascade (Flemington and Speck, 1990).
owever, the detailed mechanisms for EBV reactivation
ith TPA are yet not clear. Our present results demon-
trates an additional effect of TPA being able to decrease
onstitutive iNOS mRNA expression at an early stage of
PA treatment. L-NMMA enhanced the TPA-induced
ZLF1 and BRLF1 gene expression, suggesting the pos-
ibility that L-NMMA and TPA may interact through a
ommon mechanism in decreasing iNOS mRNA expres-
ion for the activation of BZLF1 gene.
We have previously reported that GT38 and GT39 cell
ines were EBV producers, expressing lytic antigens and
pontaneously producing infectious viruses (Takasaka et
l., 1998). However, we showed no productivity during
his study. BZLF1 mRNA and ZEBRA protein were unde-
ectable in both cell lines without stimulation for EBV
eactivation. We have also noticed that the spontaneous
BV reactivation in GT38 and GT39 cell lines changes
ith cultural conditions (data not shown). TPA-induced
ZLF1 gene expression level was always higher in GT39
ells than in GT38 cells. Conversely, the constitutive
NOS mRNA level was higher in GT38 cells than in GT39
ells. This result is consistent with the notion that spon-
aneous EBV reactivation may be controlled by endoge-
ous NO.
We do not know whether iNOS mRNA expression in
T38 and GT39 can be induced by EBV infection itself.
o iNOS mRNA expression was detected in a noncan-
erous, gastric tissue (obtained in the resected sample,
ar from the tumor itself) (Fig. 1). iNOS mRNA was also
etected in the EBV-negative epithelial A549 cell line
Mannick et al., 1994) and the EBV-negative gastric can-
er-derived, MKN-1 epithelial cell line (Hojo, 1977; Gao,
npublished data). It is predictable that a role for NO
nhibition of EBV reactivation must be common among
BV-infected cells regardless of cell types, given the
vidence for iNOS expression and the inhibition of EBV
eactivation in EBV-infected B cells (Mannick et al., 1994).
urthermore, in lymphoma-derived Akata and Mutu cells,
oth endogenous NO and NO donors inhibit reactivation
f latent EBV infection, and conversely, inhibition of en-
ogenous NO synthesis led to an increase in EBV rep-
ication, possibly by via the mechanisms that NO could
irect or indirectly downregulate expression of EBV im-
ediate-early protein Zta, by inhibiting Zta function, re-
ulting in inhibition of EBV reactivation (Mannick et al.,
994). In our present study, we have extended our un-
erstanding of the EBV reactivation mechanism to show
hat both endogenous NO and a NO donor inhibit the
xpression for the EBV immediate-early gene BZLF1.
In summary, our present results demonstrate that the
uman gastric tissue-derived epithelial cell lines GT38
nd GT39 constitutively express a low level of iNOS mRNA and that the product, NO, plays a regulatory role
n virus latency through inhibiting EBV reactivation. In
ddition, we have extended our understanding of mech-
nism and offered evidence for the generality for this
echanism regulating EBV reactivation in additional cell
ypes.
MATERIALS AND METHODS
ell lines and reagents
GT38 and GT39 cells were EBV-positive epithelial cell
ines derived from human gastric tissue (Tajima et al.,
998). EBV-positive Akata lymphoid cells (Takada and
no, 1989) and marmoset cell line B95-8 (Miller and
ipman, 1973) were used as controls. Cells were grown
n RPMI 1640 medium, supplemented with 10% fetal
ovine serum, penicillin (100 U/ml), and streptomycin
100 mg/ml), in 60-mm cell culture dishes. All cells were
ncubated in an atmosphere of 95% air and 5% CO2. For
BV reactivation, in some cases, cells were treated with
0 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA;
igma Chemical Co., St. Louis, MO). NG-monomethyl-L-
rginine (L-NMMA; Calbiochem, San Diego, CA) was
iluted in H2O to create 200 mM stock solution. S-ni-
roso-N-acetylpenicillamine (SNAP) was purchased from
igma and diluted in dimethyl sulfoxide to create 100 mM
tock solution. Mouse-anti-ZEBRA monoclonal antibod-
es were developed in our laboratory (Takasaka et al.,
998).
reparation of RNA
The total RNA from cultured cells, or from a noncan-
erous gastric tissue, was prepared by an ISOGEN Kit
Nippongene Inc., Tokyo, Japan) according to the manu-
acture’s protocol as described previously (Wang et al.,
998). Briefly, cells were lysed in the ISOGEN solution (1
l/60-mm culture plate). The homogenates of the cell
ysates were kept at room temperature for 5 min and then
reated with 0.2 ml chloroform for 3 min. The mixture was
entrifuged at 12,000 g for 15 min at 4°C. The upper
queous phase was collected, treated with 0.5 ml iso-
ropanol for 10 min, and centrifuged for 10 min at 4°C.
he RNA pellet was washed in 75% ethanol and dried
fter centrifugation. The RNA was dissolved in diethyl
yrocarbonate-treated water and stored at 220°C. All
NA samples had an OD260/OD280 ratio .1.50.
T–PCR analysis
The PCR was performed basically as previously de-
cribed (Mannick et al., 1994). Total RNA (1 mg) was
onverted to cDNA using random hexamers (2.5 mM,
rom RNA PCR Core Kit, Perkin Elmer, Branchburg, NJ) as
rimers with murine leukemia virus reverse transcriptase
2.5 U/ml) in a buffer compatible with PCR containing: 5
M MgCl2, 50 mM NaCl, 10 mM Tris–HCl, RNase inhib-
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380 GAO, TAJIMA, AND SAIRENJItor (1 U/ml), and 1 mM each dNTP (dATP, dGTP, dCTP
nd dTTP). A final volume of 20 ml was used. The reac-
ion mixture was incubated at 42°C for 1 h, heated to
4°C for 5 min to denature the reverse transcriptase, and
ooled on ice for 5 min. As primers for PCR, two oligo-
ucleotides for the human iNOS were chosen according
o the sequence of GenBank Accession No. X73029. The
equences of sense and antisense primers used for
mplification of specific human iNOS cDNA are as fol-
ows: sense primer, 59-CTGTCCTTGGAAATTTCTGTT-39;
ntisense primer, 59-GTGATGGCCGACCTGATGTTGC-39;
o amplify a 729-bp nucleotide product. The oligonucle-
tides of the “housekeeping gene” human beta-tubulin
GenBank Accession No. V00599) were designed as 59-
GGATCTAGAACCTGGGACCAT-39 (sense primer) and
9-ACCATGTTGACTGCCAACTTGC-39 (antisense primer)
o amplify a 577-bp product. The primers were synthe-
ized by Pharmacia-Japan Co., Tokyo, Japan. Of a total of
0 ml, 3 ml of the resulting cDNA was PCR amplified in
5-ml reactions. The PCR conditions were 60 s of dena-
uration at 95°C, 60 s of annealing at 62°C, and 60 s of
xtension at 72°C for 36 cycles. The amplified PCR
roducts were analyzed after electrophoresis in a 1.2%
garose gel, blot-transferred to Hybond-N1 nylon mem-
rane (Amersham, Buckinghamshire, United Kingdom),
nd UV-autocross-linked. The membranes for iNOS and
ubulin were prehybridized with prehybridization buffer
nd then hybridized with the labeled probes. The hybrid-
zed PCR product was visualized by autoradiography as
or Northern blotting described below. Each illustrated
T–PCR Southern blotting was representative of at least
hree separate experiments performed at different times.
equencing of PCR products
iNOS and tubulin PCR product were subcloned in a
GEM-T Easy vector (Promega, Madison, WI), and 10
lones of each product were sequenced by the
ideoxynucleotide chain termination method as de-
cribed elsewhere (Shastry and Trese, 1997).
orthern blot analysis
Northern blot analysis was carried out by the method
escribed previously (Wang et al., 1998). Total RNA sam-
les were denatured in 50% formamide and 2.2 M form-
ldehyde at 57°C for 15 min. Aliquots containing 20 mg of
otal RNA were loaded into a 1% agarose gel containing
.2 M formaldehyde and electrophoresed with a running
uffer containing 50 mM MOPS-acetate (pH 7.0), 10 mM
odium acetate, and 1 mM EDTA. Ribosomal RNAs (28S
nd 18S) were visualized under UV light after ethidium
romide staining to ensure the integrity of RNA samples.
he RNA was then transferred to Hybond-N1 mem-
ranes by capillary transfer and UV autocross-linked. rybridization
Membranes were prehybridized in 53 SSPE (13
SPE 5 180 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH
.4), 50% formamide, 53 Denhardt’s solution, 1% sodium
odecyl sulfate (SDS), and 200 mg salmon sperm DNA/
l, for 6 h at 42°C. The prehybridization solution was
hen replaced with fresh hybridization solution contain-
ng the labeled probe at a final concentration of 1 3 106
pm/ml and hybridization continued for 24 h at 42°C. The
lots were washed three times at 65°C in 13 SSPE, 0.1%
DS for 10 min. The blots were exposed to Kodak X-AR
ilm (Eastman Kodak Co., Rochester, NY) at 280°C for
–3 days. Relative mRNA levels were quantitated by
hosphor image system (Moleculler Imager, Nippon BIO-
AD Laboratories KK, Tokyo, Japan). After hybridization
ith the BamHI Z fragment of the EBV genome probe
Takada et al., 1986) or iNOS probe, Northern blot mem-
ranes were stripped by boiling 5 mM EDTA/0.1% SDS.
hey were then rehybridized with a probe specific for the
lyceraldehyde-3-phosphate-dehydrogenase (GAPDH;
ellinghoff et al., 1991) to control for variations in the
mount of RNA per lane. Each Northern blot shown is
epresentative of at least three separate experiments
erformed at different times, unless otherwise specified.
estern blot analysis
Ten million cells were washed twice with ice cold PBS
nd treated with 10% trichloroacetic acid on ice for 15
in. Then they were collected in a microcentrifuge tube
nd centrifuged at 15,000 g for 5 min at 4°C. Sample
ellet was solubilized in the buffer solution containing
25 mM Tris–HCl (pH 6.8), 2.3% (w/v) lithium dodecylsul-
ate, 10% (w/v) glycerol, 5% (v/v) 2-mercaptoethanol, 10
g/ml bromephenol blue, boiled for 5 min, and then
tored at 280°C until use.
Western blot analysis was carried out on protein sam-
les (50 mg per lane) which had been separated elec-
rophoratically in 10% SDS–polyacrylamide gel and elec-
rophoratically transferred onto plyvinylidene difluoride
embranes (Milliporeco, Co. Bedford, MA), using a
emidory transfer blot system. Equal amount of protein
ere blotted onto the membranes, as confirmed by Coo-
asis brilliant blue R-250 staining. The non-specific re-
ction was blocked by soaking the membranes for 2 h in
BS–Tween 20 solution containing 5% non-fat dry milk
owder (blocking buffer) at room temperature. The
locked membranes were then incubated overnight at
°C with anti-ZEBRA monoclonal antibodies (1:500) in
locking buffer. Blots were washed in blocking buffer
hree times and then incubated with the labeled rabbit-
nti-mouse IgG second antibodies in the identical block-
ng buffer for 1 h, followed by the chemiluminescence
eaction and exposed to x-ray film.
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